BuildTek Home
AI security threat research, pharma leadership analysis, strategic insights, and regulatory intelligence for CISOs, pharmaceutical executives, and healthcare leaders — from BuildTek's editorial team.
AI & Cyber Risk
Machine-speed phishing, 80-90% autonomous espionage campaigns, and weaponized AI agents. An executive analysis of AI security risks, AI governance, and the 2026 CISO defense agenda.
Read Executive Briefing
MCP Security
How attackers hijack autonomous coding agents and LLM tools through poisoned tool schemas, indirect prompt injection, and rogue MCP servers. A 6-point CISO blueprint.
Read Technical Guide
Red Teaming
Systematic methodology for adversarial testing: automated fuzzing, multi-turn cognitive priming jailbreaks, and production guardrail benchmarks mapped to MITRE ATLAS.
Read Red Team Guide
EU AI Act
Navigating Annex III classifications, Article 50 transparency obligations, and €35M fine exposure. A 7-point technical conformity audit checklist.
Read CISO Playbook
Agentic AI
How confused deputy exploits trick autonomous AI agents into executing unauthorized tools, database writes, and external network egress. Zero-trust tool defenses.
Read Exploit Analysis
Shadow AI
Detecting unmonitored local LLM runtimes (Ollama, LM Studio) and unvetted browser plugins that exfiltrate sensitive code beyond corporate security perimeters.
Read DLP Blueprint
Breach Forensics
Forensic breakdown of Equifax, Capital One, MOVEit, Heartland, and Change Healthcare: $20B+ lessons, systemic failure patterns, and the OWASP LLM security controls required for modern enterprise AI.
Read Case Studies
Patent Strategy
Blockbuster drugs worth $200B+ lose exclusivity in 2026. Here's the strategic playbook for pharma executives facing biosimilar competition and portfolio gaps.
Read Article
AI & Discovery
AI promises to compress the drug discovery timeline from decades to years. Where is the technology actually delivering — and where is the hype still outpacing results?
Read Article
Supply Chain
Geopolitical disruption, API concentration risk, and climate events are reshaping pharmaceutical supply chains. What resilient looks like now.
Read Article
Manufacturing
Continuous manufacturing, digital twins, and AI-driven quality control — how Pharma 4.0 is moving from pilot to production floor.
Read Article
Leadership
Beyond CPD hours — the real ROI that senior pharma leaders report from virtual conclaves: deals, intelligence, and rare peer conversations.
Read Article
Market Access
As the biosimilar wave crests, first-mover advantage is evaporating. This is the differentiation and market access playbook for 2026.
Read Article
Regulatory
FDA, EMA, and WHO are converging on stricter data integrity frameworks. What this means for quality heads and compliance officers in 2026.
Read Article
Public Health
Drug-resistant Candida auris is spreading across continents. How the antifungal pipeline crisis exposes systemic R&D gaps the industry must address now.
Read Article
Antivirals
The JN.1 sub-variant surge exposed critical gaps in the antiviral pipeline. A frank assessment of what pharma must build to be ready for the next wave.
Read Article
IP & Litigation
Compounded semaglutide, black-market GLP-1s, and a flood of patent litigation. The Eli Lilly playbook reveals the strategic IP battle defining pharma's next decade.
Read Article